Every July, a yellow ribbon appears for a cancer that most people have never knowingly encountered. Sarcoma is genuinely rare in adults, accounting for only about 1% of adult cancers, and yet that reassuring fraction hides something crueler: it strikes children and teenagers far out of proportion to its overall numbers, which is a large part of why it steals so many young lives. It is uncommon enough that most physicians will finish their careers having seen only a handful of cases, and common enough among the young to be devastating when it does appear.
The scale, once you look, is not small at all. Each year in the United States, the American Cancer Society estimates roughly 13,900 new soft-tissue sarcomas and another 4,100 primary bone cancers, close to 18,000 people, and about 7,600 of them will die. Those numbers only look modest beside the cancers that dominate headlines, research budgets, and awareness campaigns, and that relative invisibility is precisely the problem we want to spend this month on.
“Forgotten cancer” is not a slogan so much as a description of what happens when a disease is too rare to be familiar. It gets caught late, because no one is looking for it. It gets treated by generalists who rarely see it, because specialists are few and far between. And it gets left out of the national conversation, which is upstream of the funding that might change any of the above. Each of those gaps costs patients real time and real outcomes, and each one turns out to be more fixable than it first appears.
Over the next thirty-one days, we are going to walk through the evidence a piece at a time: why sarcoma is missed, why the place you are treated changes whether you live, why the first surgery matters more than any that follow, and why, for far too many families, the barrier between them and the care that works is not medicine at all but distance and cost. That last barrier is the one we exist to remove, by funding the travel, lodging, and gas that get sarcoma patients to the specialist centers the research keeps pointing toward. Follow along, and share the posts that land, because for a disease this overlooked, being seen is the first thing that changes outcomes.